- Home
- LYEL vs ZVRA Comparison
LYEL vs ZVRA Comparison
Compare LYEL & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYEL | ZVRA |
|---|---|---|
| Founded | 2018 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.1M | 472.9M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | LYEL | ZVRA |
|---|---|---|
| Price | $22.27 | $8.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $25.00 | $21.71 |
| AVG Volume (30 Days) | 95.9K | ★ 540.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.27 |
| EPS | N/A | ★ 1.16 |
| Revenue | $61,000.00 | ★ $23,612,000.00 |
| Revenue This Year | N/A | $333.64 |
| Revenue Next Year | N/A | $44.19 |
| P/E Ratio | ★ N/A | $7.73 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.39 | $6.19 |
| 52 Week High | $45.00 | $13.16 |
Technical Indicators
Market Signals| Indicator | LYEL | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.81 | 47.42 |
| Support Level | $21.27 | $8.61 |
| Resistance Level | $27.30 | $8.99 |
| Average True Range (ATR) | 2.12 | 0.34 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 26.16 | 33.54 |
Price Performance
Historical ComparisonAbout LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
About ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.